



# MEDICARE DRUG PRICE NEGOTIATIONS: impact on healthcare development and patient access to medicines

Wednesday, 26 July 2023 | 10:00 am – 12:30 pm (EDT)  
Online Event

This webinar examines how the Medicare price negotiation provision can be considered a type of price-setting policy, similar to the European-style price control policies applied to medicines. It also seeks to gain an understanding from healthcare providers about the perceived threat that government price setting could pose regarding access to medicines for patients. Experiences with cost containment efforts in different countries and their impact on patient care and the healthcare professional will be discussed.

- |   |   |
|---|---|
| 10:00 – 10:05                           | <b>Welcoming and webinar objectives</b><br><b>Michael S Reilly</b> , Esq, Executive Director, Alliance for Safe Biologic Medicines, USA   |
| 10:05 – 10:10                           | <b>Welcome remarks</b><br><b>Steven Stranne</b> , MD, JD, Partner, Foley Hoag LLP, USA  |
| 10:10 – 10:25                           | <b>The creation of Medicare Part D</b><br><b>Thomas R Barker</b> , Esq, JD, Partner, Foley Hoag LLP, USA  |
| 10:25 – 10:40                           | <b>Introduction of Medicare drug price provision and Maximum Fair Price (MFP) determination</b><br><b>Charles M Clapton</b> , Vice President, Federal Government Affairs, Gilead Sciences, USA  |
| 10:40 – 10:50                           | <b>Why Medicare drug price negotiation is really European price controls and what that means for patients</b><br><b>Thomas R Barker</b> , Esq, JD, Partner, Foley Hoag LLP, USA   |
| 10:50 – 11:05                           | <b>Negotiating drug prices in the US—lessons from Europe</b><br><b>Matias Olsen</b> , Public Affairs & Policy Manager, EUCOPE, Belgium  |
| 11:05 – 11:20                           | <b>Impact of IRA's small molecule penalty on cancer drug innovation</b><br><b>Steven J Potts</b> , PhD, Biotech drug developer. ICAN, International Cancer Advocacy Network, USA  |
| 11:20 – 11:35                           | <b>Pharmacist perspective on the impact of drug price controls</b><br><b>Professor Philip J Schneider</b> , MS, FASHP, FASPEN, FFIP, Ohio State University; Former Vice President of the International Pharmaceutical Federation (FIP)  |
| 11:35 – 11:50                           | <b>Medicare drug price negotiations – government price setting diminished access to medicines for patients</b><br><b>Andrew Spiegel</b> , Esq, Executive Director, Global Colon Cancer Association, USA   |
| 11:50 – 12:30<br>Moderator<br>Panelists | <b>Panel discussion and Q&amp;A</b><br><b>Steven Stranne</b> , MD, JD<br><b>Michael S Reilly</b> , Esq<br><b>Thomas R Barker</b> , Esq<br><b>Charles M Clapton</b><br><b>Matias Olsen</b><br><b>Steven J Potts</b> , PhD<br><b>Professor Philip J Schneider</b> , MS<br><b>Andrew Spiegel</b> , Esq |

[\*\*Register >\*\*](#)